HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: ERC-08-0038v1 15/3/833    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Algire, C. Articles by Pollak, M. Search for Related Content PubMed PubMed Citation Articles by Algire, C. Articles by Pollak, M.

¹ , Division of Experimental Medicine² Department of Oncology, Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Cot Ste. Catherine, Montreal, Quebec, H3T 1E7 Canada

(Correspondence should be addressed to M Pollak; Email: michael.pollak{at}mcgill.ca)

We investigated the effects of metformin on the growth of lewis lung LLC1 carcinoma in C57BL/6J mice provided with either a control diet or a high-energy diet, previously reported to lead to weight gain and systemic insulin resistance with hyperinsulinemia. Forty-eight male mice were randomized into four groups: control diet, control diet+metformin, high-energy diet, or high-energy diet+metformin. Following 8 weeks on the experimental diets, selected groups received metformin in their drinking water. Three weeks following the start of metformin treatment, mice were injected with 0.5x10⁶ LLC1 cells and tumor growth was measured for 17 days. By day 17, tumors of mice on the high-energy diet were nearly twice the volume of those of mice on the control diet. This effect of diet on tumor growth was significantly attenuated by metformin, but metformin had no effect on tumor growth of the mice on the control diet. Metformin attenuated the increased insulin receptor activation associated with the high-energy diet and also led to increased phosphorylation of AMP kinase, two actions that would be expected to decrease neoplastic proliferation. These experimental results are consistent with prior hypothesis-generating epidemiological studies that suggest that metformin may reduce cancer risk and improve cancer prognosis. Finally, these results contribute to the rationale for evaluation of the anti-neoplastic activity of metformin in hyperinsulinemic cancer patients.

This article has been cited by other articles:

				M. Pollak Macronutrient Intake and Cancer: How Does Dietary Restriction Influence Tumor Growth and Why Should We Care? Cancer Prevention Research, August 1, 2009; 2(8): 698 - 701. [Abstract] [Full Text] [PDF]

				J. A. Menendez, A. Vazquez-Martin, F. J. Ortega, and J. M. Fernandez-Real Fatty Acid Synthase: Association with Insulin Resistance, Type 2 Diabetes, and Cancer Clin. Chem., March 1, 2009; 55(3): 425 - 438. [Abstract] [Full Text] [PDF]